Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated March 2, 2026, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries and marketing products in around 170 countries. The filing details transactions executed under a programme initiated on February 4, 2026.
Key Financial Metrics
The filing focuses on capital allocation via share buybacks rather than operational financial performance metrics such as revenue or profit.
- Total Repurchase Programme Cap: Up to DKK 15 billion over a 12-month period starting February 4, 2026.
- Current Sub-Programme Cap: Up to DKK 3.8 billion for the period from February 4, 2026, to May 4, 2026.
- Shares Repurchased (as of Feb 27, 2026): 4,045,000 B shares.
- Total Transaction Value: DKK 1,160,693,639.
- Average Purchase Price: DKK 286.95 per B share.
- Treasury Shares Held: 21,434,799 B shares (0.5% of total share capital).
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Since the previous announcement on February 23, 2026, the company executed five additional transactions between February 24 and February 27, 2026. These transactions increased the accumulated number of repurchased shares from 2,750,000 to 4,045,000 and the total transaction value from DKK 841,997,435 to DKK 1,160,693,639.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the total programme limit of DKK 15 billion during the 12-month period beginning February 4, 2026. The company operates under the "Safe Harbour Rules" of the EU Market Abuse Regulation (MAR).
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard regulatory framework for share repurchases. The company notes that details for each transaction are published on its website.
Investor Verification Checklist
- Verify the remaining capacity under the DKK 15 billion total programme and the DKK 3.8 billion sub-programme.
- Confirm the current market price of B shares relative to the average repurchase price of DKK 286.95.
- Review the full transaction history on novonordisk.com for any updates post-February 27, 2026.
- Check the latest quarterly or annual report for operational financial metrics (revenue, profit, cash flow) as they are not included in this specific filing.